Immuno-effector characteristics of peritoneal cells during CAPD treatment: a longitudinal study.
Peritoneal cells (PC) from 75 patients were immuno-phenotypically and functionally characterized during the first year of CAPD treatment (PCcapd) and compared to PC obtained by laparoscopy of healthy women (control peritoneal cells). Patients were divided, according to their peritonitis incidence (PI), into a high PI (HPI) and a low PI group (LPI). The yield of PCcapd decreased significantly over the year. The differential cell count and immunophenotype of PCcapd remained unchanged in the LPI group, but the percentage of macrophages decreased over the year in the HPI group. Macrophages in the PCcapd, when compared to control peritoneal cells, had a less mature phenotype as measured by RFD7 expression but a higher Fc-receptor expression. The PCcapd showed a higher percentage of B cells, CD4 positive T cells and activated T cells bearing HLA-DR/DQ when compared to the control peritoneal cells. Over the year a decrease in chemotactic activity of the PCcapd towards 10(-8) M N-formylmethionyl-leucyl-phenylalanine and dialysis effluent was observed in LPI patients but not in HPI patients. After one year of treatment, a significantly higher percentage of phagocytosing macrophages in the PCcapd of HPI patients was found when compared to LPI patients. During the year there was an increase of immunophagocytosis of PCcapd independent of PI. In conclusion, the CAPD peritoneal cellular immune system showed signs of both immaturity and activation. The decrease in the yield and in the chemotactic activity of PCcapd suggests an adaptation to the chronic stimulus of the dialysis fluid.(ABSTRACT TRUNCATED AT 250 WORDS)
Betjes
M G
MG
Department of Cell Biology, Vrije Universiteit, Academic Medical Center, Amsterdam, The Netherlands.
Tuk
C W
CW
Struijk
D G
DG
Krediet
R T
RT
Arisz
L
L
Hoefsmit
E C
EC
Beelen
R H
RH
D000293:Adolescent; D000328:Adult; D000368:Aged; D002452:Cell Count; D002454:Cell Differentiation; D002633:Chemotaxis; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007676:Kidney Failure, Chronic / Q000276:immunology / Q000628:therapy; D008264:Macrophages / Q000166:cytology / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010529:Peritoneal Cavity / Q000166:cytology*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D010538:Peritonitis / Q000209:etiology; D010587:Phagocytosis; D011961:Receptors, Fc; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology; D013997:Time Factors
D011961:Receptors, Fc